Is Carl Icahn Going for Genzyme?

| About: Sanofi (SNY)

That's what the folks at Fierce Biotech are saying. No doubt he sees an opening, given the company's current manufacturing troubles, and is planning to give them the same treatment he's been giving Biogen (NASDAQ:BIIB), just down the road. There are quite a few glossy condominium units available in Cambridge these days; maybe Icahn should buy one as a pied-a-terre if he's going to keep this stuff up.

But I hope that he doesn't. While I agree that it's worth having some corporate raiders around to keep companies on their toes, I think the nature of the biotech industry keeps things lively enough already. I tend to agree with Schumpeter's ideas about "creative destruction", but I worry that Icahn slips too often over to the "noncreative but lucrative" end of the destruction scale.

About this article:

Tagged: , Drug Manufacturers - Major, France
Problem with this article? Please tell us. Disagree with this article? .